ライフサイエンスコーパス: coagulation test

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 Ab1 showed anticoagulant activity by global coagulation tests.

2 tivity, but demonstrate inhibition of global coagulation tests.

3 gulation and other analytical limitations of coagulation tests.

4 f normal cFIX antigen levels, which improved coagulation tests.

5 The method could extend and improve current coagulation testing.

6 etry panels, parathyroid hormone assays, and coagulation testing.

7 bin 16 g/dl), with normal liver function and coagulation testing.

8 Coagulation testing aids anesthesiologists in diagnosis

9 anding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation o

10 nificant coagulopathy (as defined by routine coagulation tests) and is used to justify preprocedure u

11 itory effect on PL-restricted in vitro blood coagulation tests, and are comprised mainly of Ab agains

12 val, expression levels, in vitro and in vivo coagulation tests, and histopathology for up to 16 month

13 s been reinforced by the fact that screening coagulation tests (APTT, prothrombin time--INR) are ofte

14 Global coagulation tests are most useful in detecting overt con

15 In addition, in most patients, coagulation tests are not sensitive to increases in coag

16 Routine coagulation tests are poor determinants of bleeding risk

17 with TBI have abnormalities on conventional coagulation tests at admission to the emergency departme

18 lation has been difficult using conventional coagulation tests, but thrombocytopenia, fibrin polymeri

19 , although some of the more widely available coagulation tests can provide information that is potent

20 To measure PT/INR, conventional coagulation testing (CCT) is performed, which is time-co

21 nd shock lead to alterations in conventional coagulation tests (CCTs).

22 Coagulation tests following the administration of factor

23 mbolism or the introduction of a more global coagulation test for screening.

24 Traditional coagulation tests for assessing vitamin K status are non

25 Viscoelastic coagulation tests have been established as a rapid and r

26 n thrombin substrates and has no activity in coagulation tests or platelet aggregation.

27 ma transfusion in either correcting abnormal coagulation tests or reducing perceived risk of hemorrha

28 1% (10 of 123) of patients with any abnormal coagulation test results and 9.7% (85 of 877) of patient

29 Plasma transfusion to correct abnormal coagulation test results prior to an invasive procedure

30 clinicians in the setting of mildly abnormal coagulation test results, and there is no evidence that

31 Viscoelastic coagulation tests (such as ROTEM or TEG) have emerged as

32 ancer range from asymptomatic basic abnormal coagulation tests to massive clinical thromboembolism, w

33 Existing laboratory coagulation testing was originally designed for evaluati

34 Coagulation tests were normalized, no bleeding had occur

35 Abnormal results of coagulation tests were not correlated with an increased

36 Coagulation tests (whole blood clotting time [WBCT], act

37 dministered to address abnormal preoperative coagulation tests, with the hope to mitigate bleeding co

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。